Strategies in the design of antiviral drugs

被引：554

作者：

De Clercq, E ^{[1
]}

机构：

[1] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium

来源：

NATURE REVIEWS DRUG DISCOVERY | 2002年 / 1卷 / 01期

关键词：

D O I：

10.1038/nrd703

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

A decade ago, just five drugs were licensed for the treatment of viral infections. Since then, greater understanding of viral life cycles, prompted in particular by the need to combat human immunodeficiency virus, has resulted in the discovery and validation of several targets for therapeutic intervention. Consequently, the current antiviral repertoire now includes more than 30 drugs. But we still lack effective therapies for several viral infections, and established treatments are not always effective or well tolerated, highlighting the need for further refinement of antiviral drug design and development. Here, I describe the rationale behind current and future drug-based strategies for combating viral infections.

引用

页码：13 / 25

页数：13

共 95 条

[81] Design and synthesis of lipophilic phospharamidate d4T-MP prodrugs expressing high potency against HIV in cell culture: Structural determinants for in vitro activity and QSAR [J].

Siddiqui, AQ ;

McGuigan, C ;

Ballatore, C ;

Zuccotto, F ;

Gilbert, IH ;

De Clercq, E ;

Balzarini, J .

JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (20) :4122-4128

[82] In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RWJ-270201 [J].

Sidwell, RW ;

Smee, DF ;

Huffman, JH ;

Barnard, DL ;

Bailey, KW ;

Morrey, JD ;

Babu, YS .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (03) :749-757

[83] Arylalkylidene rhodanine with bulky and hydrophobic functional group as selective HCVNS3 protease inhibitor [J].

Sing, WT ;

Lee, CL ;

Yeo, SL ;

Lim, SP ;

Sim, MM .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (02) :91-94

[84] Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid [J].

Sintchak, MD ;

Fleming, MA ;

Futer, O ;

Raybuck, SA ;

Chambers, SP ;

Caron, PR ;

Murcko, MA ;

Wilson, KP .

CELL, 1996, 85 (06) :921-930

[85] Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities [J].

Smee, DF ;

Huffman, JH ;

Morrison, AC ;

Barnard, DL ;

Sidwell, RW .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (03) :743-748

[86] The inhibition of human cytomegalovirus (hCMV) protease by hydroxylamine derivatives [J].

Smith, DG ;

Gribble, AD ;

Haigh, D ;

Ife, RJ ;

Lavery, P ;

Skett, P ;

Slingsby, BP ;

Stacey, R ;

Ward, RW ;

West, A .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (21) :3137-3142

[87] SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo [J].

Strizki, JM ;

Xu, S ;

Wagner, NE ;

Wojcik, L ;

Liu, J ;

Hou, Y ;

Endres, M ;

Palani, A ;

Shapiro, S ;

Clader, JW ;

Greenlee, WJ ;

Tagat, JR ;

McCombie, S ;

Cox, K ;

Fawzi, AB ;

Chou, CC ;

Pugliese-Sivo, C ;

Davies, L ;

Moreno, ME ;

Ho, DD ;

Trkola, A ;

Stoddart, CA ;

Moore, JP ;

Reyes, GR ;

Baroudy, BM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (22) :12718-12723

[88] NS3 serine protease of bovine viral diarrhea virus: Characterization of active site residues, NS4A cofactor domain, and protease-cofactor interactions [J].

Tautz, N ;

Kaiser, A ;

Thiel, HJ .

VIROLOGY, 2000, 273 (02) :351-363

[89] Tipranavir (PNU-140690): A potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class [J].

Turner, SR ;

Strohbach, JW ;

Tommasi, RA ;

Aristoff, PA ;

Johnson, PD ;

Skulnick, HI ;

Dolak, LA ;

Seest, EP ;

Tomich, PK ;

Bohanan, MJ ;

Horng, MM ;

Lynn, JC ;

Chong, KT ;

Hinshaw, RR ;

Watenpaugh, KD ;

Janakiraman, MN ;

Thaisrivongs, S .

JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (18) :3467-3476

[90] Inhibition of acute-, latent-, and chronic-phase human immunodeficiency virus type 1 (HIV-1) replication by a bistriazoloacridone analog that selectively inhibits HIV-1 transcription [J].

Turpin, JA ;

Buckheit, RW ;

Derse, D ;

Hollingshead, M ;

Williamson, K ;

Palamone, C ;

Osterling, MC ;

Hill, SA ;

Graham, L ;

Schaeffer, CA ;

Bu, M ;

Huang, MJ ;

Cholody, WM ;

Michejda, CJ ;

Rice, WG .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (03) :487-494

← 1 2 3 4 5 6 7 8 9 10 →